Fresenius Kabi Colombia SAS Pharmaceutical Import Profile — Colombia (DGFT 2022–2026)

Name: Fresenius Kabi Colombia SAS Pharmaceutical Import Records from India — 4 Products, $3.7M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Fresenius Kabi Colombia SAS — Pharmaceutical Importer Profile (2026) | 4 Products, $3.7M Trade | TransData Nexus

Fresenius Kabi Colombia SAS

Pharmaceutical Importer · Colombia · Oncology Focus · $3.7M Total Trade · DGFT Verified

Fresenius Kabi Colombia SAS is a pharmaceutical importer based in Colombia with a total trade value of $3.7M across 4 products in 2 therapeutic categories. Based on 85 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Fresenius Kabi Colombia SAS sources from 1 verified Indian supplier, with Fresenius Kabi Oncology Limited accounting for 100.0% of imports.

Fresenius Kabi Colombia SAS — Import Portfolio & Supplier Network

Fresenius Kabi Colombia SAS import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Fresenius Kabi Colombia SAS?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Fresenius Kabi Oncology Limited	$3.7M	115	100.0%

Fresenius Kabi Colombia SAS sources from 1 verified Indian supplier across 98 distinct formulations. The sourcing is highly concentrated — Fresenius Kabi Oncology Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Fresenius Kabi Colombia SAS Import?

Formulation	Value	Ships
Paclitaxel INJ 300MG 50ML vial batch no 87250112ab mfg dt 04 2025 exp dt 03 2027 1855	$109.5K	3
Docetaxel INJ 20MG 1ML vial batch no 87250114aa mfg dt 04 2025 exp dt 03 2027 5963	$102.9K	3
Carboplatino INJ. 450MG/45mlv vial	$100.0K	2
Docetaxel INJ 80MG/4ML vial batch no.87240485ba, mfg. dt. 11/2024, exp. dt.	$100.0K	2
Paclitaxel INJ. 100MG/16.7ML vial batchno. 87240475aa, mfg. dt. 11/2024, exp.dt.	$100.0K	2
Docetaxel injection 80MG/4ML vial	$97.7K	2
Oxaliplatino injection 100MG/20ML vial	$95.8K	2
Paclitaxel injection 100MG/16.7ML vial	$82.5K	2
Carboplatino injection 450MG/45ML vial	$82.1K	2
Docetaxel INJ. 80MG/4ML vial batch no.	$69.2K	2
Oxaliplatino INJ. 50MG/10ML vial (batchno. 87250025aa mfg. dt. 02/2025 exp. dt. 01/2027)	$52.0K	2
Carboplatino injection 450MG/45ML vial	$50.0K	1
Docetaxel INJ. 80MG/4ML vial. b/n	$50.0K	1
Carboplatino INJ. 450MG/45ML vial.	$50.0K	1
Paclitaxel injection 100MG 16 7ML vial batch no 87230053aa mfg dt 02 2023 exp dt 01 2025 batch no 87230052aa	$50.0K	1

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Docetaxel	Oncology	$1.1M	28	2.8%	7
2	Paclitaxel	Oncology	$1.0M	25	1.3%	11
3	Oxaliplatin	Advanced Oncology	$782.8K	17	1.7%	9
4	Carboplatin	Oncology	$750.0K	15	1.1%	8

Fresenius Kabi Colombia SAS imports 4 pharmaceutical products across 2 categories into Colombia totaling $3.7M.

Fresenius Kabi Colombia SAS — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Fresenius Kabi Colombia SAS is a Colombian pharmaceutical importer and wholesaler specializing in the distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Headquartered in Bogotá, Colombia, the company operates under the legal structure of a Sociedad por Acciones Simplificada (SAS), a simplified joint-stock company. Its primary activity involves the wholesale trade of medicinal pharmaceutical products, cosmetics, and toiletries.

As a subsidiary of the global healthcare company Fresenius Kabi, Fresenius Kabi Colombia SAS plays a pivotal role in the Colombian pharmaceutical distribution network. The parent company, Fresenius Kabi, is renowned for its commitment to life, providing essential medicines and technologies for infusion, transfusion, and clinical nutrition. In Colombia, the subsidiary focuses on ensuring the availability and distribution of these critical healthcare products, thereby supporting the local healthcare infrastructure and patient care.

2Distribution Network

Fresenius Kabi Colombia SAS maintains a centralized distribution model with its primary warehouse located in Funza, Cundinamarca, a municipality near Bogotá. The facility is situated in the Parque Celta Trade complex, specifically in Bodega 22, Autopista Medellín Km 7, Funza - Cundinamarca. (mesagil.invima.gov.co) This strategic location facilitates efficient logistics and distribution throughout Colombia, ensuring timely delivery of pharmaceutical products to various regions. While the company primarily serves the Colombian market, its affiliation with the global Fresenius Kabi network suggests potential access to international distribution channels, enhancing its capacity to meet diverse healthcare needs.

3Industry Role

In Colombia's pharmaceutical supply chain, Fresenius Kabi Colombia SAS functions as a primary wholesaler and importer. The company is responsible for sourcing finished pharmaceutical formulations from international suppliers, particularly from India, and distributing them to local healthcare providers, including hospitals, clinics, and pharmacies. By importing and wholesaling these products, Fresenius Kabi Colombia SAS ensures the availability of essential medications and medical technologies critical for patient care in Colombia.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Fresenius Kabi Colombia SAS

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Fresenius Kabi Colombia SAS exhibits a high degree of supplier concentration, sourcing all its imported pharmaceutical products from a single supplier: Fresenius Kabi Oncology Limited. This supplier dependency is evident from the company's import data, which shows a total import value of $3.7 million USD across 85 shipments, all originating from this sole supplier. The top five imported products—Docetaxel, Paclitaxel, Oxaliplatin, Carboplatin, and Bortezomib—account for 100% of the company's imports from India.

This single-source dependency presents both strategic advantages and potential risks. On the positive side, a concentrated supplier base can lead to streamlined procurement processes, stronger supplier relationships, and potentially better pricing due to bulk purchasing. However, the lack of diversification also exposes the company to risks such as supply chain disruptions, price fluctuations, and dependency on the financial and operational stability of a single supplier. The absence of alternative suppliers in the import data indicates a need for strategic consideration regarding supplier diversification to mitigate potential risks.

2Supply Chain Resilience

The resilience of Fresenius Kabi Colombia SAS's supply chain is closely tied to the stability and reliability of its sole supplier, Fresenius Kabi Oncology Limited. Given the exclusive sourcing arrangement, any disruptions affecting this supplier—such as production issues, regulatory challenges, or geopolitical events—could significantly impact the company's ability to maintain a consistent supply of pharmaceutical products. The company's import data indicates a total of 85 shipments from this supplier, suggesting a consistent and ongoing relationship.

Importing Pharmaceuticals into Colombia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Colombia

1Regulatory Authority & Framework

In Colombia, the primary regulatory authority overseeing pharmaceutical imports and ensuring the safety, efficacy, and quality of medical products is the National Institute for Food and Drug Surveillance (INVIMA). INVIMA is responsible for evaluating and approving the importation of pharmaceutical products, ensuring they meet the country's health and safety standards. (mesagil.invima.gov.co)

The key legislation governing pharmaceutical imports in Colombia includes the Health Code and the Decree 677 of 1995, which establish the regulatory framework for the importation, distribution, and commercialization of pharmaceutical products. These regulations outline the requirements for obtaining marketing authorization, conducting quality control, and ensuring compliance with Good Manufacturing Practices (GMP). For Indian pharmaceutical exporters, understanding and adhering to these regulations is crucial for successful market entry and sustained operations in Colombia.

2Import Licensing & GMP

Import licensing in Colombia requires that pharmaceutical products obtain marketing authorization from INVIMA before they can be imported and distributed. This process involves submitting detailed product dossiers, including information on manufacturing processes, quality control measures, and clinical data, to demonstrate compliance with Colombian health standards. Additionally, products must be accompanied by certificates of analysis and other documentation as specified by INVIMA.

Fresenius Kabi Colombia SAS — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Fresenius Kabi Colombia SAS's product strategy focuses on the importation and distribution of oncology medications, specifically targeting treatments for various types of cancer. The company's import data reveals a concentration in oncology products, with the top five imported items—Docetaxel, Paclitaxel, Oxaliplatin, Carboplatin, and Bortezomib—accounting for 100% of its imports from India.

This strategic focus aligns with the growing demand for cancer treatments in Colombia, driven by an increasing incidence of cancer cases and a need for effective therapies. By concentrating on oncology, Fresenius Kabi Colombia SAS aims to address critical healthcare needs and establish a strong

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Fresenius Kabi Colombia SAS

What products does Fresenius Kabi Colombia SAS import from India?

Fresenius Kabi Colombia SAS imports 4 pharmaceutical products across 2 categories. Top imports: Docetaxel ($1.1M), Paclitaxel ($1.0M), Oxaliplatin ($782.8K), Carboplatin ($750.0K).

Who supplies pharmaceuticals to Fresenius Kabi Colombia SAS from India?

Fresenius Kabi Colombia SAS sources from 1 verified Indian suppliers. The primary supplier is Fresenius Kabi Oncology Limited (100.0% of imports, $3.7M).

What is Fresenius Kabi Colombia SAS's total pharmaceutical import value?

Fresenius Kabi Colombia SAS's total pharmaceutical import value from India is $3.7M, based on 85 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Fresenius Kabi Colombia SAS focus on?

Fresenius Kabi Colombia SAS imports across 2 categories. The largest: Oncology (78.7%), Advanced Oncology (21.3%).

Get Full Fresenius Kabi Colombia SAS Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.